Salix Pharmaceuticals
Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) acquired in 2010 the rights to Lumacan® from Photocure. Salix and Photocure have entered into an agreement under which the two companies will collaborate in the development and commercialization of Lumacan®. Salix now has an exclusive worldwide license to Lumacan®, excluding the Nordic region. Salix is headquartered in Raleigh, North Carolina and develops and markets prescription pharmaceutical products for the treatment of gastrointestinal diseases.
Ipsen Pharma
Photocure has entered into a strategic collaboration with Ipsen, a global specialty-driven biopharmaceutical company focused on four franchises, including uro-oncology, to commercialise Hexvix worldwide, excluding the US and Nordic region. Ipsen has a strong and well established uro-oncology franchise and will commercialise Hexvix through its dedicated urology sales force. Ipsen has its headquarter in Paris, France, and commercial presence in 49 countries. Photocure retains the rights to the product in the Nordics and the US.